Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)

Summary

Tweet2Quit is an innovative smoking cessation intervention that combines real-time online peer-to-peer support with auto messaging. In a three-group randomized controlled trial, the investigators will compare: 1) usual care, 2) Tweet2Quit-coed, and 3) Tweet2Quit-Women only.

Conditions

• Smoking Cessation

Interventions

DRUG

NRT

8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.

BEHAVIORAL

Web Guide

A website that will provide participants with access to an evidence-based set of "base" treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules.

BEHAVIORAL

Tweet2Quit

A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., "what benefits do you hope to get from quitting smoking?"). Automated pattern detection software will identify and address any problematic low tweeting within a group.

Sponsors & Collaborators

• Stanford University

  collaborator OTHER

• National Cancer Institute (NCI)

  collaborator NIH

• University of California, Irvine

  lead OTHER

Principal Investigators

• Connie (Cornelia) Pechmann, PhD, MBA, MS · University of California, Irvine

• Judith J Prochaska, PhD, MPH · Stanford University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

21 Years

Max Age

59 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2016-10-31

Primary Completion

2022-09-30

Completion

2022-09-30

FDA Drug

Yes

Countries

• United States

Study Locations